uniQure (NASDAQ:QURE) Director Sells $79,376.45 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 2,645 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $30.01, for a total transaction of $79,376.45. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $613,374.39. This represents a 11.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of uniQure stock opened at $26.45 on Monday. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The firm has a market cap of $1.67 billion, a PE ratio of -7.60 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company has a 50 day simple moving average of $21.39 and a two-hundred day simple moving average of $21.80.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently made changes to their positions in QURE. Torren Management LLC purchased a new position in shares of uniQure in the fourth quarter worth $28,000. Jones Financial Companies Lllp increased its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc purchased a new position in shares of uniQure in the fourth quarter worth $48,000. Smartleaf Asset Management LLC purchased a new position in shares of uniQure in the fourth quarter worth $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the third quarter worth $50,000. 78.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on QURE shares. HC Wainwright dropped their target price on shares of uniQure from $70.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Finally, Barclays lowered their price objective on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.